Effectiveness and cardiovascular safety of delamanid-containing regimens in adults with multidrug-resistant or extensively drug-resistant tuberculosis: A nationwide cohort study from Belarus, 2016-18

Vera Auchynka1, Ajay M.V. Kumar2,3,4, Hennadz Hurevich1, Yulia Sereda5, Varvara Solodovnikova1, Dzmitry Katovich6, Svetlana Setkina7, Askar Yedilbayev5, Aliaksandr Skrahin8, Alena Skrahina1

1Republican Scientific and Practical Centre for Pulmonology and Tuberculosis, Minsk, Belarus; 2International Union Against Tuberculosis and Lung Disease, Paris, France; 3International Union Against Tuberculosis and Lung Disease, South-East Asia Office, New Delhi, India; 4Yenepoya Medical College, Yenepoya (Deemed to be University), Mangaluru, India; 5World Health Organization, Regional Office for Europe, Copenhagen, Denmark; 6Pulmonary Centre Klinikum Mittelbaden GmbH, Baden-Baden, Germany; 7Center for Examination and Tests in Health Service, Minsk, Belarus; 8Belarusian State Medical University, Minsk, Belarus

Abstract

To address the sub-optimal treatment outcomes among patients with multidrug-resistant (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB), the National TB Programme in Belarus started using new drugs such as bedaquiline and delamanid in 2015-16. In this study, we assessed cardiovascular safety and effectiveness (culture conversion, treatment outcomes and post-treatment recurrence) of delamanid-containing regimens among adults (>18 years) with MDR-TB or XDR-TB from June 2016 to February 2018. This was a nationwide cohort study involving analysis of routinely collected programme data from the national and six regional TB hospitals. Cardiovascular adverse events (AEs) were classified as serious or not, based on international guidelines. We conducted Cox proportional hazards regression and calculated adjusted hazards ratio(aHR) and 95% confidence intervals (CI) to evaluate factors associated with AEs and unsuccessful treatment outcomes (death, failure and lost-to-follow-up). Of 125 patients enrolled (35, 28% females; mean age 43 years), 85(68%) had XDR-TB. All the patients received delamanid and 20 patients received both delamanid and bedaquiline. Cardiovascular AEs (177 episodes in total) were observed in the majority (73%) of patients but were
mild and managed easily. The most common cardiovascular AEs were QTcF prolongation (64/177, 36%) and other electrocardiography (ECG) abnormalities (40/177, 23%). There were two instances of serious AEs leading to death, both of which were not related to delamanid. In multivariable analysis, male sex (aHR 0.72; 95% CI 0.51-0.99), and baseline ECG abnormalities (aHR 1.68; 95% CI 1.19-2.36) were associated with cardiovascular AEs. Median time to culture conversion was 1.1 months (interquartile range: 1.0-2.1). Culture conversion was observed in 115 (92%) patients at six months of treatment and 110 (88%) completed the treatment successfully. Loss to follow-up, failure and death were observed in 6%, 4% and 2% patients respectively. Among those assessed at 12 months post-treatment (n=33), recurrence was seen in one patient. The only factor associated with unsuccessful treatment outcomes in multivariable analysis was baseline Hepatitis C co-infection (aHR 3.61; 95% CI 1.09-11.95). In conclusion, treatment using delamanid-containing regimens was effective and had a favourable safety profile. We hope our findings inform the development of national clinical guidelines and scale-up of new drugs in other countries.

Introduction

Tuberculosis (TB) still remains a major public health concern worldwide, even though the causal agent was discovered more than 130 years ago. The World Health Organization (WHO) estimated that ten million people developed TB in 2018 and about 15% of them died due to it. This makes TB the leading infectious cause of death globally, ranking above HIV/AIDS [1]. The global community has pledged to end the TB epidemic by 2030 in line with the sustainable development goals of the United Nations [2]. The progress towards achieving this goal has been slow and varied across the regions. Countries in the WHO European Region are progressing faster with a 5.5% annual reduction in TB incidence compared to 1.5% reduction globally [1]. One of the challenges for TB elimination worldwide and especially in the WHO European Region is the epidemic of drug resistant TB.

About half a million people developed multidrug-resistant TB (with resistance to isoniazid and rifampicin) or rifampicin-resistant TB (RR/MDR-TB) in 2018 globally and 6.2% of them had extensively drug-resistant TB (XDR-TB, with additional resistance to fluoroquinolones and second-line injectable agents). There are enormous gaps in the cascade of care – with nearly two-thirds of estimated M/XDR-TB patients worldwide not diagnosed and/or not started on treatment; of those started on treatment, only half are successfully treated [1]. The poor outcomes are primarily due to lower efficacy, serious adverse drug effects and the long duration of treatment of second line regimens [3].

New TB drugs such as bedaquiline and delamanid have been endorsed by the WHO for management of M/XDR-TB patients and are now available in Belarus for programmatic use [4]. Usage of these drugs has the potential to improve the treatment success rates, reduce the adverse drug events and reduce the duration of treatment [5].

Previous studies on the efficacy and safety of delamanid-containing regimens have shown varying results. A phase III clinical trial among MDR-TB patients showed that there is no difference in culture conversion and treatment success between delamanid and placebo containing regimens (77.1% vs 77.6%) [6,7]. It is not clear whether these results reflect actual drug efficacy or problems in trial design or implementation [8]. There have been many real-world observational studies conducted in different countries on effectiveness of delamanid containing regimens. A report from South Africa in a cohort of difficult-to-treat patients shows high culture conversion [9]. Preliminary findings from the endTB observational cohort study from 17 countries report a 80% culture conversion during first six months of therapy in cohort of patients treated with delamanid-containing regimens [10]. Meanwhile, there is limited information on final treatment outcomes and there is no information on post-treatment recurrence. A study from South Korea reported a treatment success of 82% in patients receiving delamanid [11]. There is also limited information about the effect of concomitant use of bedaquiline and delamanid [12,13]. A recent systematic review reports that the combined use of bedaquiline and delamanid had a treatment success of 71.4% and in only 2.3% of the patients either drug was stopped due to adverse events [14].

Delamanid has been generally considered safe to use [4]. The most common adverse effect reported was prolongation of QTcF interval, which was mostly mild and manageable at the programmatic level [15]. While about 9-14% of patients receiving delamanid had QTcF prolongation recorded, in less than 3% of them, QTcF prolongation exceeded 500 milliseconds [8,16-19]. Yet, information on other cardiovascular adverse events associated with administration of delamanid is limited. It is possible that adverse events are associated with other factors, which include the use of other TB and non-TB medications, antiretrovirals, and baseline clinical and behavioural profile including alcohol and drug use [19]. These factors have not been studied in detail.

Belarus is a country in eastern Europe with a high burden of drug resistant TB. The national TB programme (NTP) in Belarus has been using delamanid since 2016 under programmatic conditions and has had an efficient system of cohort event monitoring including active surveillance and reporting of adverse events [20]. This provides an opportunity to study the effectiveness (including final treatment outcomes and post-treatment recurrence) and cardiovascular safety of delamanid-containing regimen under programmatic settings. This is an important research priority identified by the NTP as well as the regional ‘European Tuberculosis Research Initiative’ (ERI-TB).

In this study, we aimed to i) describe the sociodemographic and clinical characteristics of adults with M/XDR-TB who received delamanid-containing regimens in Belarus; ii) assess the frequency and incidence of cardiovascular adverse drug events and describe their severity, timing, management and outcome; iii) assess interim and final treatment outcomes and post-treatment recurrence; and iv) assess factors associated with cardiovascular adverse drug events and unsuccessful treatment outcomes.

Materials and Methods

Study design

This was a cohort study involving analysis of secondary data routinely collected by the Belarus NTP.

Study population and study period

We included all adult (aged ≥18 years) patients with M/XDR-TB who started treatment with delamanid-containing regimens in Belarus from June 2016 to February 2018 at the Republican Scientific and Practical Centre for Pulmonology and Tuberculosis (RSPCPT) and six regional TB hospitals.
Study setting
Belarus is a country in eastern Europe with a population of 9.5 million. The Ministry of Health has the overall responsibility for the planning and implementation of the TB Programme in the country. This is done via the RSPCPT based in the capital city Minsk and the health departments of the regions of Belarus.

Diagnosis of MDR-TB and XDR-TB
The diagnosis and treatment of TB in Belarus follow the national clinical protocol, approved by the Ministry of Health [21]. Patients suspected of TB were tested at regional laboratories or the national reference laboratory located at Republican TB Centre. Appropriate specimens (sputum or any other specimen, including from an extrapulmonary site) were subjected to the following tests: sputum microscopy, Xpert MTB/RIF assay, Line Probe Assay for both first line and second-line drugs and liquid and solid culture and phenotypic drug susceptibility tests (for both first- and second-line drugs on solid and liquid media).

Treatment
Individualized treatment regimens were designed by the experts in the Republican MDR-TB Concilium taking into account DST results, history of previous treatments and outcomes, co-morbid conditions and clinical status of patient, which was in line with the WHO guidelines and clinical protocols of the NTP [4,21]. Treatment regimens were constructed in order to ensure presence of minimum of four effective drugs during the intensive phase. The drugs and dosages are shown in Supplementary Table 1. Treatment consisted of intensive phase for a period of 6-8 months and continuation phase for a period of 12-18 months. Delamanid was usually provided for a period of 24 weeks, but this was extended, if required. Patients were hospitalized for initiation of treatment. Once they become culture negative and clinically stable, patients were discharged from the hospital and referred to a health facility near to their place of residence for continuation of therapy and follow up. Delamanid was administered twice daily and all dosages were directly observed during the entire duration of therapy at inpatient and outpatient settings.

Follow-up and treatment monitoring
The treatment response was assessed once monthly, by performing sputum culture, microscopy and clinical assessment. Chest radiography is performed once every three months during intensive phase and once every six months during continuation phase. Blood tests are performed every month for assessment of electrolyte abnormalities, albumin levels, anaemia, thrombocytopenia, leukopenia, liver and renal function. Electrocardiography (ECG) is performed once every two weeks in the first month and monthly thereafter for assessment of QTcF interval and detection of arrhythmias.

Grading of adverse events
The AEs were classified according to the Medical Dictionary for Regulatory Activities (MedDRA) [22]. Grade referred to severity grading scale of adverse events. We used the Common Terminology Criteria for Adverse Events (CTCAE) to grade the adverse events [23]. There were five grades: i) Grade 1 (mild with no or minimal symptoms; requires only careful observation with no intervention); ii) Grade 2 (moderate requiring minimal, local or non-invasive intervention); iii) Grade 3 (medically significant event but not immediately life-threatening; requiring hospitalization or prolongation of hospitalization; disabling; limiting the activities of daily living); iv) Grade 4 (life-threatening consequences requiring urgent intervention); v) Grade 5 (death related to adverse event).

Serious adverse event
AEs are also classified as ‘serious AE’ or not as defined by The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). As per ICH guideline, a serious adverse event (SAE) is any untoward medical occurrence that at any dose: i) results in death or ii) is life-threatening or iii) requires inpatient hospitalization or results in prolongation of existing hospitalization or iv) result in persistent or significant disability/incapacity or v) results in a congenital anomaly/ birth defect or vi) is a medically important event or reaction [24].

The types of AEs and their grades are shown in Supplementary Table 2. Based on the AE, if the suspected drug is identified, one of the following actions is taken: intensified monitoring, dose reduction, drug stopped temporarily or permanently. Additional supportive treatment is provided, as appropriate.

Data variables and sources of data
The variables related to the study objectives were extracted from the patient charts maintained at the RSPCPT and the regional TB hospitals. These included the sociodemographic, behavioural and clinical data (diagnosis, treatment, adverse events and outcomes). We also collected information on baseline comorbidities including cardiovascular diseases and ECG abnormalities. Culture conversion was defined as obtaining two consecutive culture negative results. Final treatment outcomes were classified as successful (cured and treatment completed) and unsuccessful outcomes (death, loss to follow up, failure, not evaluated).

Data entry and analysis
The data were double entered and validated in a structured EpiData database created for the purpose of the study. Analysis was done using R software version 3.5.2 software (©R Foundation for Statistical Computing, 2016). We described the sociodemographic and clinical profile of study participants by using frequencies and proportions (for categorical variables) and mean (and standard deviation, SD) or median (and interquartile range) for continuous variables, as appropriate. The interim and final treatment outcomes were summarized using frequencies and proportions.

For analysis of AEs, we considered every event as the unit of analysis. The AEs were summarized by type of event, severity and seriousness, time of onset and duration, management and their outcome. The calculation of the incidence rate of SAEs was done by dividing the number of events by the total person-months of observation.

To evaluate associations of sociodemographic and clinical factors with unsuccessful treatment outcomes Cox proportional hazards regression was used. For SAEs, we used an extended Cox regression (The Prentice, Williams, and Peterson Total Time Model) to account for recurrent events. For both outcomes we calculated crude (HR) and adjusted hazard ratios (aHR) and 95% confidence intervals (CI). Proportionality assumption was tested using by using the Schoenfeld residuals against the transformed time. All variables met the assumption. Variables with p value <0.05 in unadjusted analysis along with
age and sex were included in the final model. If two variables were collinear, then only one of them was used in the model. We measured collinearity by Variance Inflation Factor. A p value of <0.05 was considered as statistically significant in all analyses.

Results

Patient characteristics

A total of 125 adult patients were included in the study. Majority of patients were male (90, 72%) and the mean age (SD) was 43 (12) years. In 44 (35%) of patients, there was a history of alcohol abuse and 79 (63%) were tobacco smokers (Table 1). Most (97%) of the patients had pulmonary TB and 85 (68%) had XDR-TB. The following comorbidities were reported at baseline: HIV (15%), hepatitis C (15%), diabetes mellitus (11%), hypertension (11%) and cardiovascular disorders (22%). Nearly 30% of the patients had baseline ECG abnormalities (non-specific ST segment change, T wave abnormal, overload of the right atrium) with none showing baseline QTc prolongation (Table 1). All studied patients received delamanid-containing anti-TB treatment, while 20 (16%) patients received both delamanid and bedaquiline. The median duration of delamanid use was 6 months (IQR: 5.5-8.3; range: 1.5-24 months). Nearly half (49%)

| Sociodemographic and behavioural characteristics | n   | (%) |
|--------------------------------------------------|-----|-----|
| Total                                            | 125 | (100)|
| Demographic characteristics                      |     |     |
| Age in years, mean (SD)                          | 43  | (12 )|
| Age groups, years                                |     |     |
| 18-35                                           | 37  | (30 )|
| 36-45                                           | 36  | (39 )|
| 46-55                                           | 29  | (23 )|
| 56-65                                           | 21  | (17 )|
| 66-72                                           | 2   | (2 )|
| Sex                                              |     |     |
| Male                                             | 90  | (72 )|
| Female                                           | 35  | (28 )|
| Type of residence                                |     |     |
| Urban                                            | 79  | (63 )|
| Rural                                            | 42  | (34 )|
| Not recorded                                     | 4   | (3 )|
| Homelessness                                     |     |     |
| Yes                                              | 4   | (3 )|
| No / Not recorded                                | 121 | (97 )|
| Employment                                       |     |     |
| Yes                                              | 34  | (27 )|
| No                                               | 91  | (73 )|
| Behaviour characteristics                        |     |     |
| Tobacco smoker                                    |     |     |
| Yes                                              | 79  | (63 )|
| No                                               | 46  | (37 )|
| Alcohol abuse                                    |     |     |
| Yes                                              | 44  | (35 )|
| No                                               | 81  | (65 )|
| Drug use                                         |     |     |
| Yes                                              | 6   | (5 )|
| No                                               | 119 | (95 )|

Table 1. Baseline characteristics of M/XDR-TB patients treated with delamanid-containing regimens in Belarus from June 2016 to February 2018 (N=125).

| Clinical characteristics | n   | (%) |
|---------------------------|-----|-----|
| Total                     | 125 | (100)|
| Body mass index, median (25th - 75th percentiles) | 22 | (19-24) |
| Body mass index groups    |     |     |
| Underweight (<18.5)       | 17  | (14 )|
| Normal weight (18.5-24.9) | 84  | (67 )|
| Overweight (25.0-28.9)    | 17  | (14 )|
| Obese (≥30.0)             | 7   | (6 )|
| Comorbidities at baseline |     |     |
| HIV                       | 19  | (15 )|
| Diabetes Mellitus         | 14  | (11 )|
| Hypertension              | 14  | (11 )|
| Hepatitis B               | 10  | (8 )|
| Hepatitis C               | 19  | (15 )|
| Baseline cardiovascular disorders | 28 | (22 )|
| Baseline ECG abnormalities | 37  | (30 )|
| Tuberculosis diagnostics  |     |     |
| Baseline smear microscopy |     |     |
| Positive                  | 73  | (58 )|
| Negative                  | 52  | (42 )|
| Baseline culture          |     |     |
| Positive                  | 125 | (100)|
| Negative                  | 0   | (0 )|
| Baseline Xpert MTB/Rif    |     |     |
| Positive RR+              | 69  | (55 )|
| Negative                  | 5   | (4 )|
| Not done                  | 51  | (41 )|
| Type of drug resistance   |     |     |
| MDR                       | 7   | (6 )|
| MDR (plus fluoroquinolone resistance) | 7 | (6 )|
| MDR (plus injectable resistance) | 26 | (21 )|
| XDR                       | 85  | (68 )|
| TB localization           |     |     |
| Pulmonary                 | 121 | (97 )|
| Both pulmonary and extrapulmonary      | 4   | (3 )|
| Having cavity             |     |     |
| Yes                       | 75  | (60 )|
| No                        | 50  | (40 )|
| Treatment of tuberculosis |     |     |
| History of treatment      |     |     |
| New                       | 52  | (42 )|
| Previously treated        | 73  | (58 )|
| Bedaquiline in delamanid-containing regimen    |     |     |
| Yes                       | 20  | (16 )|
| No                        | 105 | (84 )|

Data are presented as n (%) unless otherwise said; ART, antiretroviral therapy; HIV, human immunodeficiency virus; MDR, multidrug resistant; RR, rifampicin resistance; TB, tuberculosis; XDR, extensively drug-resistant.
of the patients received delamanid beyond six months of treatment. The median duration of delamanid use was 6 months (IQR: 5.5-8.3 months; Range: 1.5-24 months).

**Adverse events**

AEs were reported in all patients. There was a total of 831 AEs recorded. Of these, metabolic and nutritional disorders were the most common (193, 23%, incidence rate (IR): 7.6 per 100 person-months) followed closely by the cardiovascular AEs (177, 21%, IR: 7.0 per 100 person-months), renal disorders (107, 13%, IR: 4.2 per 100 person-months) and blood and lymphatic disorders (106, 13%, IR: 4.2 per 100 person-months) (Figure 1). The highest incidence of cardiovascular AEs was reported during the first month of treatment which declined steadily as the treatment progressed (Figure 2). The most common cardiovascular AEs were QTcF prolongation (64/177, 36%) and other ECG abnormalities (40/177, 23%) (Table 2). In total, 91 of 125 patients (73%) had cardiovascular AEs, and number of events ranged from 1 to 6 per patient. Most of the AEs were mild in nature and did not require dose adjustment or discontinuation of the drug (temporary or permanent). There were two serious cardiovascular AEs with a fatal outcome that were not related to delamanid therapy. In one patient, death occurred seven months after delamanid was discontinued and the other patient had a severe form of TB meningitis amidst the progression of HIV infection. Most (90%) of the AEs were resolved by the end of the treatment and the median time to resolve the AEs was 72 (IQR: 31-105) days.

**Treatment outcomes**

Culture conversion was observed in 115 (92%) patients at six months of treatment and 110 (88%) completed the treatment successfully (Table 3). The median time to culture conversion was 1.1 (IQR: 1.0-2.1; range 0.1-6.9) months. Unsuccessful outcomes were reported in 15 (12%) of patients: 2% death, 4% failure and 6% lost to follow-up. While there was no recurrence at 6 months after treatment, one case (1/33, 3%) of recurrence was recorded after 12 months at post-treatment. There was no statistically significant difference (p=0.41) in treatment success between the delamanid-only cohort (94/105, 89%) and delamanid-plus-bedaquiline cohort (16/20, 80%).

**Factors associated with cardiovascular AEs and unsuccessful outcomes**

In unadjusted analysis, both baseline cardiovascular disorders and baseline ECG abnormalities were associated with increased risk of AEs. Since the two variables were collinear, we included only one of them in multivariable model. In multivariable analysis, male sex (adjusted hazard ratio (aHR) 0.72; 95% CI 0.51-0.998), and baseline ECG abnormalities (aHR 1.68; 95% CI 1.19-2.36) were associated with cardiovascular AEs (Supplementary Table 4). Concomitant use of bedaquiline and delamanid was not associated with increased risk of cardiovascular AEs. Hepatitis C co-infection was the only factor associated with unsuccessful treatment outcomes both in unadjusted analysis and multivariable model controlling for sex and age was (aHR 3.61; 95% CI 1.09-11.95) (Supplementary Table 5).

**Discussion**

This is the first study from Belarus reporting on effectiveness and cardiovascular safety of delamanid-containing regimens in adults with RR/MDR-TB and XDR-TB and adds to the global evi-
idence on this issue. This is the first report globally providing information on post-treatment recurrence. This is also the largest cohort of patients ever reported from programmatic settings.

We found that delamanid-containing regimens were highly effective, safe and well-tolerated among adults with M/XDR-TB in Belarus. The 6-month culture conversion of 92%, treatment success of 88% and low recurrence post-treatment suggest a high efficacy of the regimen. These are the highest rates of culture conversion and treatment success ever reported in patients with M/XDR-TB. Previous studies reported a 6-month culture conversion ranging 74-84% and treatment success ranging 61-81% [7,10,11,13,25].

Cardiovascular AEs have been reported as one of the major

![Figure 2](image)

**Figure 2.** Cumulative incidence rate of cardiovascular adverse drug events along the follow up in M/XDR-TB patients treated with delamanid-containing regimens in Belarus from June 2016 to February 2018 (N=125). Square brackets mean the end point is included, and round parentheses mean it is excluded. For example (1, 2] means above the one and below or equal two; MDR, multidrug-resistant; TB, tuberculosis; XDR, extensively drug-resistant.

| Spectrum of cardiovascular adverse drug events and their severity in M/XDR-TB patients treated with delamanid-containing regimens in Belarus, from June 2016 to February 2018 (N=125). |
|---|---|---|---|---|---|---|
| **Proportion of patients with AE n (%)** | **IR per 100 pm [95% CI]** | **Number of AE n (%)** | **Severity grade<sup>a</sup>, n** | I | II | III |
| QTcF prolongation | 50 (40) | 2.52 [1.94-3.22] | 64 (36) | 40 | 4 | 20 |
| ECG abnormal | 36 (29) | 1.57 [1.12-2.14] | 40 (23) | 39 | – | 1 |
| Sinus tachycardia | 25 (20) | 1.10 [0.73-1.59] | 28 (16) | 28 | – | – |
| Sinus bradycardia | 19 (15) | 0.90 [0.57-1.36] | 23 (13) | 22 | 1 | – |
| Ventricular extrasystoles | 5 (4) | 0.20 [0.06-0.46] | 5 (3) | 5 | – | – |
| Bundle branch block | 5 (4) | 0.20 [0.06-0.46] | 5 (3) | 5 | – | – |
| Atrioventricular block | 3 (2) | 0.12 [0.02-0.34] | 3 (2) | 2 | 1 | – |
| Supraventricular extrasystoles | 2 (2) | 0.08 [0.01-0.28] | 2 (1) | 1 | 1 | – |
| Hypertension arterial | 2 (2) | 0.08 [0.01-0.28] | 2 (1) | – | 2 | – |
| Heart rate irregular | 1 (1) | 0.04 [0.00-0.22] | 1 (1) | 1 | – | – |
| Other cardiovascular disorders | 2 (2) | 0.08 [0.01-0.28] | 2 (1) | – | – | – |
| Other investigations | 2 (2) | 0.08 [0.01-0.28] | 2 (1) | 2 | – | – |
| Total | 91 (73) | 6.56 [5.98-8.07] | 177 (100) | 140 | 13 | 22 |

<sup>a</sup>Denominator for the percentage: total sample of the study participants; <sup>b</sup>Denominator for the percentage: total number of respective adverse event occurrences; <sup>c</sup>grade description: I = mild, II = moderate, III = severe, IV = life-threatening, V = fatal; AE, adverse event; CI, confidence interval; IR, incidence rate; MDR, multidrug-resistant; QTcF, adjusted QT interval using Fredericia formula; TB, tuberculosis; XDR, extensively drug-resistant; ECG, electrocardiogram.
concerns when treating with delamanid and bedaquiline. Although nearly three-fourths of patients in our study experienced cardiovascular AEs, most of these were mild and did not require any dose adjustment, discontinuation of drug or treatment. Serious cardiovascular AEs were observed only in two patients and in both cases were not related to delamanid, which is in line with previous studies [17]. The highest incidence of cardiovascular AEs was reported during the first month of the treatment and decreased with the treatment time. This may indicate that there was no cumulative toxicity effect of delamanid-containing regimens related to overall quantity of drug consumed.

Globally and in the WHO European region, the treatment success rates among RR/MDR-TB patients (57%) and XDR-TB patients (39%) have been low and far below the regional target of 75%. The results obtained in this study hold promise that the target of 75% can be met and exceeded, provided there is access to and rational use of new drugs embedded in a well-performing NTP with an active drug safety monitoring system.

In a sub-group analysis, we found that there was no significant difference in treatment success or risk of cardiovascular AEs between patients who received both bedaquiline and delamanid and those who received delamanid only, although the numbers were small, and we were not adequately powered for this analysis. There have been concerns that using both bedaquiline and delamanid together may act synergistically and increase the risk of cardiodotoxicity. Our findings are reassuring because there was no increase in risk of cardiovascular AEs when both drugs were used simultaneously. There were some other interesting findings. Male sex and baseline ECG abnormalities (also baseline cardiovascular disorders) were associated with higher risk of cardiovascular AEs. There have been concerns that using both bedaquiline and delamanid together may act synergistically and increase the risk of cardiovascular AEs. The highest incidence of cardiovascular AEs was reported during the first month of the treatment and decreased with the treatment time. This may indicate that there was no cumulative toxicity effect of delamanid-containing regimens related to overall quantity of drug consumed.

Recurrence

At 6 months° 0/106 (0)
At 12 months* 1/33 (3)

Among patients who were eligible for 6-month follow-up assessment after completion of anti-TB treatment (N=106), *among patients who were eligible for 12-month follow-up assessment after completion of anti-TB treatment (N=33); TB, tuberculosis; MDR, multidrug-resistant; XDR, extensively drug-resistant.

Table 3. Treatment outcomes and post-treatment recurrence in M/XDR-TB patients treated with delamanid-containing regimens in Belarus, 06/2016 - 02/2018 (N=125).

| Characteristics                  | n/N  | (%) |
|----------------------------------|------|-----|
| Interim treatment outcomes       |      |     |
| Culture negative at 6 months of anti-TB treatment | 115/125 | (92) |
| Final treatment outcomes        |      |     |
| Treatment success                | 110/125 | (88) |
| Cured                            | 110/125 | (88) |
| Treatment completed              | 0/125  | (0)  |
| Unsuccessful outcome             | 15/125 | (12) |
| Treatment failed                 | 5/125  | (4)  |
| Died                             | 3/125  | (2)  |
| Lost to follow-up                | 7/125  | (6)  |

Recurrence at 6 months of anti-TB treatment.

At 6 months° 0/106 (0)
At 12 months* 1/33 (3)

Among patients who were eligible for 6-month follow-up assessment after completion of anti-TB treatment (N=106), *among patients who were eligible for 12-month follow-up assessment after completion of anti-TB treatment (N=33); TB, tuberculosis; MDR, multidrug-resistant; XDR, extensively drug-resistant.

Conclusions

We found that treatment of adult patients with RR/MDR-TB and XDR-TB patients using delamanid-containing regimens in Belarus was effective and had a favourable cardiovascular safety profile. Nearly nine in ten patients were successfully treated with low rates of post-treatment recurrence. Although the majority of patients experienced cardiovascular AEs, most of them were mild and could be managed easily. Our results provide robust evidence for countries in the WHO European region and elsewhere to introduce and scale-up the use of new drugs.

References

1. WHO. Global tuberculosis report 2019. Geneva; 2019. Accessed on: 2019 Nov 20. Available from: https://www.who.int/tb/publications/global_report/en/
2. United Nations. Transforming our world: the 2030 agenda for sustainable development transforming our world: the 2030 agenda for sustainable development. 2016.
3. Halleux CM, Falzon D, Merle C, et al. The world health organization global aDSM database: generating evidence on the safety of new treatment regimens for drug-resistant tuberculosis. Eur Respir J 2018;51:1701643.
4. WHO. Consolidated guidelines on drug-resistant tuberculosis...
treatment. Geneva; 2019 Accessed on: 2019 Nov 20. Available from: https://www.ncbi.nlm.nih.gov/books/NBK539517/
5. Migliori GB, Tiberi S, Zumla A, et al. MDR/xdr-tb management of patients and contacts: challenges facing the new decade. the 2020 clinical update by the global tuberculosis network. Int J Infect Dis 2020;92:S15-25.
6. WHO. Position statement on the use of delamanid for multidrug-resistant tuberculosis. Geneva; 2019 Accessed on: 2019 Nov 22. Available from: https://www.who.int/tb/publications/2018/WHOPositionStatementDelamanidUse.pdf?ua=1
7. von Groote-Bidlingmaier F, Patientia R, Sanchez E, et al. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial. Lancet Respir Med 2019;7:249–59.
8. Pontali E, Centis R, D’Ambrosio L, et al. Recent evidence on delamanid use for rifampicin-resistant tuberculosis. J Thorac Dis 2019;11:S457-60.
9. Mohr E, Hughes J, Reuter A, et al. Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa. Eur Respir J 2018;51:1800017.
10. Seung KJ, Khan P, Franke MF, et al. Culture conversion at six months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2020;71:415-8.
11. Mohr E, Hughes J, Reuter A, et al. Delamanid and bedaquiline in combination for treatment of drug-resistant tuberculosis in patients with rifampicin resistance: a randomised controlled trial. Lancet Infect Dis 2019;19:1261-2.
12. Gupta R, Keister LJ, Hafkin J, et al. Delamanid and QT prolongation in the treatment of multidrug-resistant tuberculosis. Tubere Lung Dis 2015;19:1203-9.
13. Kempker RR, Mikiashvili L, Zhao Y, et al. Clinical outcomes among patients with drug-resistant tuberculosis receiving delamanid and bedaquiline containing regimens. Clin Infect Dis 2019. doi: 10.1093/cid/ciz1107